There are over 120 types of brain tumour and approximately 45% of primary brain tumours are gliomas, of which glioblastoma multiforme (GBM) is the most common and aggressive with a median survival rate of 14 months. Despite progress in our knowledge, current therapies are unable to effectively combat primary brain tumours and patient survival remains poor. Tumour metabolism is important to consider in therapeutic approaches and is the focus of numerous research investigations. Lactate dehydrogenase A (LDHA) is a cytosolic enzyme, predominantly involved in anaerobic and aerobic glycolysis (the Warburg effect), however it has multiple additional functions in non-neoplastic and neoplastic tissues, which are not commonly known or discussed. This review summarises what is currently known about the function of LDHA and identifies areas that would benefit from further exploration. The current knowledge of the role of LDHA in the brain and its potential as a therapeutic target for brain tumours will also be highlighted. The Warburg effect appears to be universal in tumours, including primary brain tumours, and LDHA (due to its involvement with this process) has been identified as a potential therapeutic target. Currently, there are, however, no suitable LDHA inhibitors available for tumour therapies in the clinic.